Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:accessories |
addressed by company
|
| gptkbp:activities |
neutralizes virus
|
| gptkbp:availability |
limited during trials
|
| gptkbp:business_model |
adhered to guidelines
|
| gptkbp:clinical_trial |
diverse demographics
multiple countries Phase 3 randomized controlled trials pending publication multiple phases conducted reduction in symptoms |
| gptkbp:collaborations |
academic institutions
various healthcare organizations |
| gptkbp:collection |
systematic approach
|
| gptkbp:committee |
established
consulted |
| gptkbp:community_engagement |
informed public about trials
|
| gptkbp:developed_by |
gptkb:Amgen
|
| gptkbp:developer |
2020-present
|
| gptkbp:dosage_form |
varies by trial
|
| gptkbp:education |
provided during trials
|
| gptkbp:effective_date |
under review
|
| gptkbp:feedback |
collected during trials
|
| gptkbp:future_plans |
exploring combination therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amgen's COVID-19 treatment
|
| gptkbp:invention |
patented
|
| gptkbp:investment |
high demand
|
| gptkbp:is_effective_against |
reduces hospitalization risk
|
| gptkbp:is_monitored_by |
required during treatment.
|
| gptkbp:is_tested_for |
under investigation
|
| gptkbp:manager |
intravenous
|
| gptkbp:marketed_as |
brand name TBD
|
| gptkbp:notable_work |
shared with medical community
|
| gptkbp:outcome |
conducted regularly
|
| gptkbp:partnerships |
biotech firms
|
| gptkbp:products |
filed
|
| gptkbp:provides_information_on |
developed for use
|
| gptkbp:publishes |
gptkb:academic_journal
peer-reviewed |
| gptkbp:receives_funding_from |
public and private sectors
|
| gptkbp:recruitment |
ongoing
|
| gptkbp:regulatory_body |
gptkb:FDA
|
| gptkbp:regulatory_compliance |
sought in multiple regions
|
| gptkbp:research_focus |
COVID-19 variants
|
| gptkbp:safety_features |
ongoing
monitored in trials reported to authorities |
| gptkbp:scientific_goals |
improve treatment outcomes
|
| gptkbp:side_effect |
infusion reactions
reported in trials aims to reduce burden |
| gptkbp:student_enrollment |
specific criteria
|
| gptkbp:supply_chain |
global distribution
|
| gptkbp:target_audience |
COVID-19 patients
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:training |
conducted for administration
|
| gptkbp:treatment |
evaluated in studies
monitored post-treatment established for trials |
| gptkbp:type |
gptkb:monoclonal_antibody
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
5
|